Singapore markets close in 57 minutes
Straits Times Index
3,306.09 -15.99 (-0.48%) Nikkei
39,134.79 +96.63 (+0.25%) Hang Seng
18,192.55 -174.40 (-0.95%) FTSE 100
8,238.59 +10.11 (+0.12%) Bitcoin USD
67,536.62 -1,747.29 (-2.52%) CMC Crypto 200
1,401.02 -40.62 (-2.82%)
PCVX Jul 2024 80.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:44AM EDT. Market open.
| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 80.00 |
| Expiry date | 2024-07-19 |
| Day's range | 3.0000 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.